Trametinib (Mekinist®) is accepted for restricted use within NHSScotland.
Accepted for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation in combination with dabrafenib. Restricted for use after first line treatment.
Source:
Scottish Medicines Consortium